OT-7999

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: OT-7999
• 英文别名: 5-Butyl-8-(4-trifluoromethyl-phenyl)-3H-[1,2,4]triazolo[5,1-i]purine；5-butyl-8-[4-(trifluoromethyl)phenyl]-1H-[1,2,4]triazolo[5,1-f]purine
• 化学式: C₁₇H₁₅F₃N₆
• 分子量: 360.342
• InChiKey: IOICVMMVGWPRCC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  26
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  71.8
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  4-(三氟甲基)亚苯基肼 、 methyl N-(4-cyano-1-imidazol-5-yl)pentanimidate 以69%的产率得到OT-7999
  参考文献：
  名称：

  1,2,4-三唑并[5,1-i]嘌呤衍生物为高效和选择性的人腺苷A（3）受体配体。

  摘要：

  一系列的三唑并尿烷与人腺苷A（3）受体拮抗剂9-氯-2-（2-呋喃基）-5-[（苯乙酰基）氨基] [1,2,4]三唑并[1,5-] c]喹唑啉（MRS 1220，1）。在这项研究中，我们发现新颖的1,2,4-三唑并[5,1-i]嘌呤衍生物（2）显示人腺苷A（3）受体亲和力。该化合物分两步从5-氨基-4-氰基咪唑（33）中获得。亲和力是在放射性配体结合试验中确定的，用于克隆的人腺苷A（1），A（2A），A（2B）和A（3）受体。分析了结构-活性关系后，我们确定在5位的烷基长度与A（3）受体的亲和力之间存在温和的抛物线关系，并且在8位的苯基上取代基的长度与亲和力之间呈正相关在A（2A）受体上。这些研究导致有效和选择性的人类腺苷A（3）受体配体。最有效的A（3）受体配体（5-正丁基-8-（4-甲氧基苯基）-3H- [1,2,4]三唑并[5,1-i]嘌呤（27，K（i）= 0.18 nM）和针对A

  DOI：

  10.1021/jm010570p

文献信息

• Pyrazine Derivatives Useful as Adenosine Receptor Antagonists
  申请人：Vidal Juan Bernat

  公开号：US20090042891A1

  公开（公告）日：2009-02-12

  The present disclosure relates to a compound of formula (I) wherein: A is an optionally substituted monocyclic or polycyclic aryl or heteroaryl group; B is an optionally substituted monocyclic nitrogen-containing heteroaryl group; and either a) R 1 and R 2 are chosen from a hydrogen atom and specified substituents, or b) R 2 , R 1 and the —NH— group to which R 1 is attached, form a moiety chosen from the moiety of formulae (IIa) and (IIb): or a pharmaceutically acceptable salt thereof, or a N-oxide thereof. The present disclosure also relates to a method for treating a subject afflicted with a pathological condition or disease susceptible to amelioration by antagonism of the A 2B adenosine receptor.

  本公开涉及一种式（I）的化合物，其中：A是可选取的取代的单环或多环芳基或杂芳基基团；B是可选取的取代的单环含氮杂芳基基团；并且要么a）R1和R2选择自氢原子和指定的取代基，要么b）R2、R1和R1附着的—NH—基团形成式（IIa）和（IIb）的基团：或其药学上可接受的盐或其N-氧化物。本公开还涉及一种治疗患有病理状况或疾病，易于通过拮抗A2B腺苷受体而改善的受试者的方法。
• PYRAZINE DERIVATIVES USEFUL AS ADENOSINE RECEPTOR ANTAGONISTS
  申请人：Vidal Juan Bernat

  公开号：US20100273757A1

  公开（公告）日：2010-10-28

  The present invention provides a compound of formula (I) wherein: A represents an optionally substituted monocyclic or polycyclic aryl or heteroaryl group B represents an optionally substituted monocyclic nitrogen-containing heteroaryl group; and either a) R 1 and R 2 represent hydrogen or specified substituents, or b) R 2 , R 1 and the —NH— group to which R 1 is attached, form a moiety selected from the moiety of formulae (IIa) and (IIb): (IIa) These compounds are useful as antagonists of the A2B receptor, for instance in the treatment of asthma.

  本发明提供了一种式为（I）的化合物，其中：A代表可选取代的单环或多环芳基或杂芳基基团；B代表可选取代的单环含氮杂芳基基团；并且要么a）R1和R2代表氢或指定的取代基，要么b）R2，R1和R1连接的—NH—基团形成从式（IIa）和（IIb）中选择的基团：（IIa）这些化合物可用作A2B受体拮抗剂，例如在哮喘治疗中。
• Facile synthesis of fused 1,2,4-triazolo[1,5-c]pyrimidine derivatives as human adenosine A3 receptor ligands
  作者：Takashi Okamura、Yasuhisa Kurogi、Kinji Hashimoto、Hiroshi Nishikawa、Yoshimitsu Nagao

  DOI：10.1016/j.bmcl.2004.03.010

  日期：2004.5

  A facile synthetic method for fused triazolopyrimidine derivatives having high affinity and selectivity for human adenosine A(3) receptors is reported. The fused triazolopyrimidine derivatives were easily prepared by one-pot reaction using acylhydrazines and imidates prepared from amine derivatives bearing cyano group and orthoesters in situ. This synthetic method was useful in finding new tricyclic adenosine A3 receptor antagonists and also in diversifying the substituents at two positions on the fused triazolopyrimidine ring. (C) 2004 Elsevier Ltd. All rights reserved.
• TRIAZOLOPURINE DERIVATIVES, MEDICINAL COMPOSITION CONTAINING THE DERIVATIVES, ADENOSINE A3 RECEPTOR COMPATIBILIZING AGENT, AND ASTHMATIC REMEDY
  申请人：OTSUKA PHARMACEUTICAL FACTORY, INC.

  公开号：EP1069126B1

  公开（公告）日：2003-05-28
• A3 ADENOSINE RECEPTOR LIGANDS FOR MODULATION OF PIGMENTATION
  申请人：Oradin Pharmaceutical Ltd.

  公开号：EP2456419A1

  公开（公告）日：2012-05-30